Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a pioneering clinical-stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products. These novel drugs aim to treat significant diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs, Seres is at the forefront of creating the first therapeutics that induce a shift towards health by enhancing the microbiome's biology.
The company operates primarily in the United States, leveraging its microbiome therapeutics platform to develop Ecobiotic™ microbiome therapeutics. These therapies are designed to restore health by repairing the function of a dysbiotic microbiome, particularly in the colon. Seres' lead product, SER-109, is developed to prevent the recurrence of Clostridium difficile infection (CDI), a severe infection of the colon. Additional product candidates include SER-262, SER-287, and SER-401.
Recently, Seres announced the sale of its VOWST assets to Nestlé Health Science under a non-binding memorandum of understanding. This transaction will provide Seres with capital infusions, including an upfront payment, and is expected to be completed in the next 90 days, subject to shareholder approval and other conditions. VOWST, the first FDA-approved oral microbiome therapy, prevents the recurrence of CDI in adults following antibacterial treatment for recurrent CDI.
Seres plans to use the capital from this transaction to retire its existing debt and strengthen its financial position. The company is also advancing SER-155, evaluated in a Phase 1b study in patients undergoing allogeneic hematopoietic stem cell transplantation. SER-155 has the potential to reduce gastrointestinal and related bloodstream infections, as well as acute graft-versus-host disease.
Seres Therapeutics continues to innovate in microbiome therapeutics, aiming to benefit multiple underserved patient groups, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The company's approach could protect millions of medically vulnerable patients from life-threatening infections while addressing the global public health issue of antimicrobial resistance (AMR).
Seres Therapeutics has secured a
The initial
With VOWST's FDA approval in April 2023, Seres aims to lead in microbiome therapeutics. The partnership with Oaktree is vital for Seres’ growth, addressing significant medical needs.
Seres Therapeutics announced that the FDA has approved VOWST (fecal microbiota spores, live-brpk), the first orally administered microbiota-based therapeutic for preventing recurrent C. difficile infection (CDI) in adults post-antibacterial treatment. The approval follows the successful Phase 3 ECOSPOR III study, which indicated that 88% of treated patients were recurrence-free at eight weeks. VOWST is expected to be available in June 2023, with a milestone payment of $125 million to Seres from Nestlé Health Science linked to the FDA approval. The joint commercialization effort aims to address a significant unmet medical need as recurrent CDI is a leading cause of hospital-acquired infections. The product does not treat CDI but aims to prevent its recurrence.
On April 5, 2023, Seres Therapeutics (Nasdaq: MCRB) announced the granting of inducement equity awards totaling 22,000 shares to three new employees. This includes options for 11,000 shares and restricted stock units (RSUs) for another 11,000 shares. The stock options have an exercise price of $5.61 per share and will vest over a specified schedule, rewarding employees for their service. This grant is part of the 2022 Employment Inducement Award Plan, which allows the company to incentivize new employees under Nasdaq rules. This announcement is part of Seres' strategy to attract and retain talent in the competitive biotech sector, enhancing its operational capacity to develop microbiome therapeutics.
Seres Therapeutics, a leading microbiome therapeutics company (Nasdaq: MCRB), announced that CEO Eric Shaff will present at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 8:40 a.m. ET. The presentation will be accessible via an audio webcast on Seres' website, with a replay available for 21 days after the event.
Seres is pioneering novel multifunctional bacterial consortia aimed at treating diseases. Its SER-109 program has achieved positive clinical results, gaining FDA Breakthrough Therapy and Orphan Drug designations for preventing recurrent C. difficile infections. The company is also advancing SER-155 in a Phase 1b study targeting gastrointestinal infections and other conditions.
Seres Therapeutics (MCRB) reported its 2022 financials and business updates, highlighting the FDA's review of its SER-109 Biologics License Application, with a target decision date of April 26, 2023. SER-109 is an oral microbiome therapeutic aimed at recurrent C. difficile infection (rCDI), showing an 88% success rate in preventing recurrence in trials. Commercial launch is expected soon after FDA approval. The company also advances SER-155, with preliminary data expected in May 2023. Despite a significant net loss of $250.2 million in 2022, Seres anticipates a $125 million milestone payment upon SER-109's approval.
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced on March 1, 2023, the grant of inducement equity awards totaling 15,500 shares to three new employees. The awards comprise 9,250 stock options and 6,250 restricted stock units (RSUs), issued under the Company's 2022 Employment Inducement Award Plan.
The options have an exercise price of $5.15 per share and will vest over time, with 25% vesting after one year and the remainder vesting quarterly. This plan aims to attract talent in compliance with Nasdaq rules.
FAQ
What is the current stock price of Seres Therapeutics (MCRB)?
What is the market cap of Seres Therapeutics (MCRB)?
What does Seres Therapeutics, Inc. do?
What is SER-109?
What recent transaction did Seres Therapeutics announce?
What is VOWST?
What is the financial condition of Seres Therapeutics?
Who founded Seres Therapeutics?
What other products are in Seres Therapeutics' pipeline?
What partnerships does Seres Therapeutics have?
What is the company's approach to treating diseases?
Where can I find more information about Seres Therapeutics?
